Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PBMs Will Emerge From “Regulatory Cloud” Soon, Express Scripts Predicts

Executive Summary

The investigations of pharmacy benefit management practices will take up to three more years to resolve, Express Scripts CFO Edward Stiften predicted during the Bear Stearns conference in New York Sept. 13

You may also be interested in...

PBMs Still In Prosecutors’ Sights; Express Scripts Faces Spitzer

New York Attorney General Eliot Spitzer's suit against Express Scripts represents another high-profile challenge to the pharmacy benefit management business model at a time when the industry hopes to play a prominent role in the Medicare drug benefit

Medco Settlement Sets “Gold Standard” For PBMs Ahead Of Medicare Rx

Prosecutors expect that other pharmacy benefit management companies will adopt codes of conduct based on Medco's April 26 settlement with 20 state attorneys general and the U.S. Attorney in Philadelphia

TAP, Express Scripts Receive Boston Subpoenas Related To Lupron, Prevacid

TAP Pharmaceuticals is responding to a second request for documents related to Lupron and Prevacid from the Boston U.S. Attorney's Office





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts